Etiology, pathogenesis, clinical features, points of convergence and differences in - minimal cognitive impairment (MCI) Alzheimer's disease (AD) including also non-cognitive aspects vascular dementia cerebral amyloid angiopathy (CAA) Parkinson's disease (PD), PD dementia, atypical PD Non motor symptoms in PD Lewy body dementia (LBD) frontotemporal dementia (FTD) movement disorders other than PD (Tics, Restless Legs Syndrome, Dystonia) schizophrenia neurodevelopment and neurodegeneration Genetics of AD and PD Neurogenetics of AD, PD, FTD; genetic basis for responsiveness to approved drugs and pharmacogenomics Epidemiology and pharmacoeconomics in dementia and PD Biomarkers, diagnostics and genetic aspects of neurodegenerative diseases Neuroimaging - its role in early diagnosis and evaluation of clinical trials in MCI, AD, PD, LBD Functional neuroimaging in PD and other movement disorders Leading hypotheses on neurodegeneration, major risk factors and culprits in neurodegenerative diseases such as AD, PD, LBD, CAA, FTD Physiological and pathological role of β-amyloid, intracellular β-amyloid, its precursors, β-amyloid modulation and removal Tau and mechanistic aspects Oxidative stress, apolipoprotein-E, axonal transport and others; mechanistic aspects in neurodegeneration AD, PD, LBD, FTD: Animal models Potential disease modification in AD (α -, β - and γ- secretases as targets; prevention of β -amyloid aggregation) Treatment and potential disease modification in AD, CAA {direct and receptor-mediated modulation of kinases involved in the etiopathogenesis) Cholinergic treatments in neurodegenerative diseases via cholinomimetics (cholinesterase inhibitors, cholinergic agonists and others) Role of cholesterol in β -amyloid modulation - basic and therapeutic aspects in AD Low molecular weight glycosaminoglycans and β-sheet breakers as potential agents in the treatment of neurodegenerative disorders Immunotherapies and related strategies in AD Mechanism and treatment strategies in PD, PD dementia and atypical PD Treatment of motor and non motor symptoms and complications in PD Dopamine agonists and neuroprotection in PD and related disorders LBD: Basic and therapeutic strategies (e.g. prevention of α-synuclein aggregation) α-Synuclein and proteosome system in PD and related disorders Stem cells, gene therapies, surgical strategies and others in neurodegenerative diseases The impact of proteomics in AD/PD research

			Home | Welcome Note | List of Topics | Timetable | Scientific Program | Invited Speakers Committees | Confirmed Sponsors Sponsorship & Exhibition | Call for Abstracts General Information | Accommodation | Registration | Previous Conference | Useful Links